nitrosourea


Also found in: Wikipedia.

nitrosourea

 [ni-tro″so-u-re´ah]
any of a group of cell cycle phase nonspecific, lipid soluble biological alkylating agents, including carmustine, lomustine, semustine, and streptozocin; they cross the blood-brain barrier and are used as antineoplastic agents. Streptozocin is an antibiotic that contains a nitrosourea group and differs somewhat in action from the other three.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

ni·tro·so·ur·e·a

(nī-trō'sō-ūr'ē-ă),
Alkylating agent used in the treatment of many neoplasms; an example is BCNU.
Farlex Partner Medical Dictionary © Farlex 2012

nitrosourea

Oncology Any of a group of lipid-soluble alkylating anticancer drugs–carmustine–BCNU, lomustine–CCNU, which cross the blood-brain barrier, and are used to manage brain tumors
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
To assess the role of STAT3 in gastric carcinogenesis, we induced gastric cancer in [Stat3.sup.[DELTA]gec] mice using the chemical carcinogen Nmethyl-N- nitrosourea (MNU) [33, 37, 38].
At eleven weeks after the surgeries, all rats were injected with streptozotocin (STZ), which is a nitrosourea analog and selectively induces pancreatic beta cell death by alkylation of DNA (Delaney et al.
Other second-line options for patients with good performance status include high-dose interleukin-2 (not suitable for patients with inadequate organ reserve, poor performance status, or untreated or active brain metastases), biochemotherapy and cytotoxic agents (dacarbazine or temozolomide, and cisplatin or carboplatin, with or without vinblastine or nitrosourea, and IL-2 and interferon alfa-2b; paclitaxel, albumin-bound paclitaxel).
Mechanism of comutagenesis of sodium arsenite with N- methyl-N- nitrosourea. Biol.
(1) demonstrated that resistance acquired by tumor cells during treatment with alkylating agents (nitrosourea and carmustine/BCNU) was maintained by intermittent treatment with low concentrations of chemotherapy agents.
The reported cooperative effects of MJ with other drugs are shown in Table 3: (1) BCNU (carmustine), an alkylating nitrosourea agent with no cytotoxic effect on pancreatic carcinoma cell line MIA PaCa-2 in vitro combined with MJ showed enhanced cell death [170].
Each wafer contains the nitrosourea alkylating agent carmustine distributed in a biodegradable polymer matrix.
The product is intended to treat adult patients that have been recently diagnosed with glioblastoma multiforme, concomitantly with radiotherapy and then as maintenance treatment and also refractory anaplastic astrocytoma patients whose disease has progressed on a drug regimen containing nitrosourea and procarbazine.